Physician profile
Anna Pollard
NPI 1518346238
$2,733.14
in general payments reported to CMS, 2019-2025
24 companies · $364 in 2025
The $364 reported for 2025 was more than what 79% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $447 · 2022: $436 · 2023: $841 · 2024: $645 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,836 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.43 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $386.01 | 2023-2025 | Veozah |
| Novo Nordisk INC | $341.25 | 2023-2025 | Wegovy |
| Abbvie INC. | $334.48 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $207.31 | 2021 | |
| Genzyme Corporation | $183.77 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $167.36 | 2023-2024 | |
| Boston Scientific Corporation | $151.28 | 2023 | |
| Shield Therapeutics INC | $136.66 | 2023-2024 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $126.68 | 2024 | |
| Amgen INC. | $122.84 | 2021 | |
| Impel Pharmaceuticals INC. | $102.97 | 2023 | Trudhesa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.56 | 2021 | |
| Molnlycke Health Care US, LLC | $73.06 | 2022 | |
| Exeltis, USA INC. | $63.02 | 2024 | Slynd |
| Lilly USA, LLC | $36.58 | 2024 | Zepbound |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.78 | 2024 | |
| Coopersurgical, INC. | $28.82 | 2025 | Paragard T 380a |
| Millicent US INC | $27.97 | 2024 | Intrarosa, Femring |
| Organon LLC | $23.57 | 2024 | |
| Therapeuticsmd, INC. | $20.92 | 2022 | |
| Phadia US INC. | $19.51 | 2022 | |
| Pfizer INC. | $19.09 | 2024 | |
| Hologic Sales and Service, LLC | $17.46 | 2022 | |
| Avion Pharmaceuticals | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Pollard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.